Navigation Links
China Botanic Sees Strong Initial Demand from Guangzhou Military Region
Date:12/9/2010

HARBIN, China, Dec. 9, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (NYSE Amex: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company has received a significant number of purchase orders totaling approximately $0.3 million since it won a major one-year contract bid to supply its all-natural products to the Guangzhou Military District.  The main products supplied under the contract include the Company's Siberian Ginseng series and other traditional OTC products.

China Botanic is the leader in the production and development of Siberian Ginseng products, which possess scientifically-proven medical benefits in treating depression and enhancing quality of sleep. The Guangzhou Military District is one of the China's most important military administrative regions and includes military hospitals and other medical facilities in Hubei, Hunan, Guangdong and Hainan provinces, as well as in Hong Kong and Macau.  

"Building a cooperative relationship with the military procurement network diversifies our sales channels," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are delighted to see strong initial sales as a result of our contract with the Guangzhou Military District, which reflects the effectiveness of our marketing strategies.  We will continue to explore additional sales channels both within and outside of China's public sector.  In addition to the success of our sales team, we are honored that the Guangzhou Military Region looks to China Botanic for plant-based remedies."  

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China.  All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to expand its Ginseng and Deer Antler Extract product sales, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact: China Botanic Pharmaceutical Inc.Ms. Portia Tan, IR ContactTel: 86-451-8260-2162Email: ir@renhuang.com CCG Investor Relations:Mr. Mark Collinson, PartnerPhone: +1-310-954-1343 (Los Angeles)Email: mark.collinson@ccgir.comWebsite: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email: crocker.coulson@ccgir.com
'/>"/>

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoStem Announces Agreement With Shijiazhuang Third Hospital in the Provincial Capital of Hebei Province, China to Offer Orthopedic Applications Based on NeoStem’s Licensed Technology
2. Reportlinker Adds China Pharmaceutical Market Overview
3. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
4. China-Biotics Attended National Probiotics Seminar
5. China Medical Technologies, Inc. Announces the Closing of US$150 Million Convertible Senior Note Offering and the Completion of Repurchase of US$105.9 Million Convertible Notes Due 2011
6. China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program
7. Recent NDRC Pricing Concessions Not Expected to Impact China Sky Ones Portfolio of Products
8. China Medical Technologies Reports Second Fiscal Quarter Financial Results
9. China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2010
10. China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results
11. China Medicine Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... the healthcare industry, ranked among the top five firms in the “2015/2016 Best ... HIT Implementation Support and Staffing. KLAS is a research and insights firm on ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans ... Catholic health care system that’s partnering with Intel on value-based health benefits program ...
(Date:2/11/2016)... SURPRISE, ARIZ. (PRWEB) , ... February 11, 2016 , ... ... kids,” a group of men, 60 and older, who gather once a year to ... , Besides a love for the game, the more than 50 players who competed ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... exhibiting at the American Academy of Dermatology Annual Meeting at the Walter E. ... is to raise awareness for both the condition of hyperhidrosis (excessive sweating) and ...
Breaking Medicine News(10 mins):